# Pre-activation of T cell immunity potentiates ferroptotic cell death through arachidonic acid hybridized nanovesicles

**Authors:** Qi Lyu, Chang Liu, Shaoyue Li, Dandan Shan, Hong Han, Liying Wang, Huixiong Xu

PMC · DOI: 10.1186/s12951-025-03797-x · Journal of Nanobiotechnology · 2025-11-18

## TL;DR

A new strategy pre-activates T cells to boost immune response and enhance ferroptotic tumor cell death using nanovesicles.

## Contribution

A dual strategy using engineered nanovesicles to pre-activate T cells and induce ferroptosis in tumors.

## Key findings

- Pre-activation of T cells with OMVs increases IFN-γ production in the tumor microenvironment.
- Combining OMVs with MLipoAA leads to significant tumor destruction and reduced recurrence/metastasis in CT26 xenografts.
- IFN-γ synergizes with arachidonic acid to trigger Acsl4-mediated ferroptosis in tumor cells.

## Abstract

Ferroptotic tumor therapy is of highly significance to treat malignancies. Nevertheless, immune cells within the tumor immune microenvironment (TIME) are particularly susceptible to ferroptosis upon exposure to ferroptotic inducers, leading to the immunosuppression of TIME. In the present work, we report a dual activation strategy to initially pre-activate the T cells within TIME using genetically engineered cytolysin A-expressing outer membrane vesicles (OMVs) to enhance the interferon-γ (IFN-γ) production. We then deliver the homologous tumor cell membrane-hybridized liposomal nanovesicles containing arachidonic acid (MLipoAA) to the tumor cells for IFN-γ-potentiated ferroptosis. The combination treatment of OMVs and MLipoAA results in significant tumor destruction in colon CT26 tumor xenografts. This approach is also effective in combating tumor recurrence and metastasis. Mechanistically, the produced IFN-γ synergizes with arachidonic acid to trigger Acsl4-mediated tumor ferroptosis. The present work provides prominent immunopotentiations followed by selective tumor ferroptotic strategy with high effectiveness and biocompatibility, presenting a robust therapeutic strategy to conquer the immunosuppression drawback during in vivo ferroptotic therapy.

Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death

Pre-Activation of T cell Immunity Potentiates Tumor Ferroptotic Cell Death

The online version contains supplementary material available at 10.1186/s12951-025-03797-x.

## Linked entities

- **Genes:** ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182]
- **Proteins:** IFNG (interferon gamma)
- **Chemicals:** arachidonic acid (PubChem CID 444899)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** ACSL4 (acyl-CoA synthetase long chain family member 4) [NCBI Gene 2182] {aka ACS4, FACL4, LACS4, MRX63, MRX68, XLID63}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}
- **Diseases:** malignancies (MESH:D009369), metastasis (MESH:D009362)
- **Chemicals:** arachidonic acid (MESH:D016718), Ferroptotic (-)
- **Cell lines:** CT26 — Mus musculus (Mouse), Mouse colon adenocarcinoma, Cancer cell line (CVCL_7254)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12625620/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12625620/full.md

---
Source: https://tomesphere.com/paper/PMC12625620